Health activist, scholar, award-winning journalist, and cancer survivor Sharon Batt investigates the relationship between patient advocacy groups and the pharmaceutical industry as well as the contentious role of pharma funding. Over the past several decades, a gradual reduction in state funding has pressured patient groups into forming private-sector partnerships. This analysis of Canada's breast cancer movement from 1990 to 2010 shows that the resulting power imbalance undermined the groups' ability to put patients' interests ahead of those of the funders. A movement that once encouraged democratic participation in the development of health policy now eerily echoes the demands of the pharmaceutical industry.

The increasing resistance of bacteria to antibiotics, and pests to pesticides, threatens to undo some of the most remarkable advances made in public health and agriculture during the past century. Though the potential consequences of increased antibiotic and pesticide resistance are far reaching, regulatory efforts to address the problem are at a very early stage. Battling Resistance to Antibiotics and Pesticides moves such discussions forward by presenting cutting edge research and the first comprehensive application of economic tools to analyze how antibiotics and pesticides should be used to maximize their value to society. Laxminarayan and his contributors explore lessons from past experiences with resistance, especially in agriculture. They consider what incentives would be ideal for the individuals who prescribe or apply antibiotics and pesticides, and what would be ideal for the firms engaged in developing and producing these products. The chapters in this groundbreaking book reflect the fact that efforts to combat resistance will require contributions from a broad range of scholars and professionals, representing a broad range of expertise. The analysis demonstrates that, for all these participants, an understanding of economic issues is an essential complement to knowledge of medical or biological factors. The book provides economists with an overview of relevant scientific issues, as well as a variety of analytical approaches to studying the economics of resistance. It offers policymakers detailed analyses of the multiple dimensions of resistance and discusses the future strategies to combat and manage resistance. For professionals in medicine, public health, and agriculture, the book translates the economic approaches into usable guidance for daily practice and decisionmaking.

Although many books have been written about the economic impact of globalization on Europe, none has focused exclusively on the pharmaceutical industry. To fill this gap in scholarship, "Globalization and Industrial Relations" offers a full account of how open markets have affected drug companies, their employees, and consumers alike.
Using the examples of Germany and the United Kingdom as case studies, this volume uses a careful theoretical background and broad empirical analysis to evaluate the current state of industrial relations in the pharmaceutical industry. "Globalisation and Industrial Relations" addresses how companies in the pharmaceutical industry deal with the challenges from globalization in respect to collective bargaining and workplace representation. A complete analysis of industrial relations in the drug manufacturing industry in a changing world, this volume also forecasts different trajectories for the systems of industrial relations in Germany and the United Kingdom.

This book evaluates the performance of the Indian pharmaceutical industry, which plays an important role in economic development. It highlights the role the government has had in facilitating the growth of the industry from non-existence, before the 1970s, to being one of the largest pharmaceutical industries in the world today. The text employs various useful techniques to provide an understanding of productivity and efficiency, such as data envelopment analysis, stochastic frontier analysis, the Malmquist Productivity Index and the Hicks-Moorsteen Productivity Index. The book will be useful to health administrators, students of public policy, and health economists with an interest in the pharmaceutical sector.